Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents

Clinical Infectious Diseases

Volumn 48, Issue 10, 2009, Pages 1441-1458

  Brüggemann, Roger J M ^a,b,c   Alffenaar, Jan Willem C ^a   Blijlevens, Nicole M A ^a,c   Billaud, Eliane M ^d   Kosterink, Jos G W ^a   Verweij, Paul E ^b,c   Burger, David M ^a,c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Nijmegen Institute for Infection   (Netherlands)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; AMITRIPTYLINE; ANTACID AGENT; ANTIFUNGAL AGENT; CARBAMAZEPINE; CIMETIDINE; DIDANOSINE; ESOMEPRAZOLE; FAMOTIDINE; FLUCONAZOLE; FLUTICASONE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYITRACONAZOLE; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; MEVINOLIN; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; POSACONAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; TERFENADINE; TRIAZOLAM; UNINDEXED DRUG; VINCRISTINE; VORICONAZOLE; PYRROLE DERIVATIVE;

ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; DRUG MONITORING; DRUG URINE LEVEL; FOOD; FOOD DRUG INTERACTION; GENETIC POLYMORPHISM; GRAPE JUICE; HUMAN; MYCOSIS; NUTRITIONAL SUPPORT; PHARMACOKINETICS; PREDICTION; PRIORITY JOURNAL; REVIEW; STOMACH PH; URINARY EXCRETION; VOLUNTEER;

ANTIFUNGAL AGENTS; AZOLES; DRUG INTERACTIONS; HUMANS;

EID: 65549159077     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598327     Document Type: Review

References (206)

1. Eagling VA, Tjia JF, Back DJ. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 1998;45:107-14.
2. Guengerich FP. Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem Biol Interact 1997;106:161-82.
3. US Food and Drug Administration (FDA). Center for Drug Evaluation and Research. Drugs@FDA: FDA approved drug products. DIFLUCAN. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction = Search.Overview&DrugName =DIFLUCAN. Accessed 7 January 2008.
4. Pfaff G, Zimmermann T, Lach P, Yeates R, Simon G, Wildfeuer A. Pharmacokinetics and tolerance of fluconazole suppositories in healthy volunteers. Arzneimittelforschung 1993;43:391-5.
5. Buijk SL, Gyssens IC, Mouton JW, Verbrugh HA, Touw DJ, Bruining HA. Pharmacokinetics of sequential intravenous and enteral flucon- azole in critically ill surgical patients with invasive mycoses and compromised gastrointestinal function. Intensive Care Med 2001;27:115-21.
6. Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother 1985;28:648-53.
7. Dudley MN. Clinical pharmacology of fluconazole. Pharmacotherapy 1990;10(6 Pt 3):S141-5.
8. Foulds G, Wajszczuk C, Weidler DJ, Garg DJ, Gibson P. Steady state parenteral kinetics of fluconazole in man. Ann N Y Acad Sci 1988;544:427- 30.
9. de Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs 2001; 61(Suppl 1):27-37.
10. US Food and Drug Administration (FDA). Center for Drug Evaluation and Research. Drugs@FDA: FDA approved drug products. Search results for "sporanox." Available at: http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm. Accessed 7 January 2008.
11. Barone JA, Moskovitz BL, Guarnieri J, et al. Enhanced bioavailability of itraconazole in hydroxypropyl-b-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 1998;42:1862-5.
12. Arredondo G, Martinez-Jorda R, Calvo R, Aguirre C, SuarezE. Protein binding of itraconazole and fluconazole in patients with chronic renal failure. Int J Clin Pharmacol Ther 1994;32:361.
13. Grant SM, Clissold SP. Itraconazole. Areview ofits pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989;37:310-44.
14. Tucker RM, Denning DW, Dupont B, Stevens DA. Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med 1990;112: 108-12.
15. Bailey EM, Krakovsky DJ, Rybak MJ. The triazole antifungal agents: a review of itraconazole and fluconazole. Pharmacotherapy 1990;10: 146-53.
16. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother 2002;46:160-5.
17. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Klei- nermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002;46:2546-53.
18. European Medicines Agency (EMEA). EPARs for authorised medicinal products for human use. Vfend. Available at: http://www.emea.europa.eu/htms/human/epar/ v.htm. Accessed 7 January 2008.
19. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003;37:728-32.
20. Verweij PE, Brinkman K, Kremer HP, Kullberg BJ, Meis JF. Aspergillus meningitis: diagnosis by non-culture-based microbiological methods and management. J Clin Microbiol 1999;37:1186-9.
21. Nulens E, Eggink C, Rijs AJ, Wesseling P, Verweij PE. Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole. J Clin Microbiol 2003;41:2261-4.
22. Klont RR, Eggink CA, Rijs AJ, Wesseling P, Verweij PE. Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole. Clin Infect Dis 2005;40:e110-2.
23. Hariprasad SM, Mieler WF, Holz ER, et al. Determination ofvitreous, aqueous, and plasma concentration of orally administered voricon-azole in humans. Arch Ophthalmol 2004;122:42-7.
24. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006;45:649-63.
25. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003;56(Suppl 1):10-6.
26. Purkins L, Wood N, Greenhalgh K, Eve MD, Oliver SD, Nichols D. The pharmacokinetics and safety of intravenous voriconazole-a novel wide-spectrum antifungal agent. Br J Clin Pharmacol 2003;56(Suppl 1):2-9.
27. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003;31:540-7.
28. European Medicines Agency (EMEA). EPARs for authorised medicinal products for human use. Noxafil. Available at: http://www.emea.europa.eu/htms/human/ epar/n.htm. Accessed 7 January 2008.
29. Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003;47:2788-95.
30. Keating GM. Posaconazole. Drugs 2005;65:1553-67.
31. Sansone-Parsons A, Krishna G, Simon J, et al. Effects of age, gender, and race/ethnicityon the pharmacokinetics ofposaconazole inhealthy volunteers. Antimicrob Agents Chemother 2007;51:495-502.
32. Ghosal A, Hapangama N, Yuan Y, et al. Identification of human UDP- glucuronosyltransferase enzyme(s) responsible for the glucuronida- tion of posaconazole (Noxafil). Drug Metab Dispos 2004;32:267-71.
33. Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004;48:3543-51.
34. Barone JA, Moskovitz BL, Guarnieri J, et al. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy 1998;18:295-301.
35. Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 2003;56(Suppl 1):17-23.
36. Krishna G, Moton A, Ma L, et al. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. Clin Ther 2009;31:286-98.
37. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of po- saconazole in healthy adults. Br J Clin Pharmacol 2004;57:218-22.
38. Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004;48:804-8.
39. Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect ofa nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006;50:1881-3.
40. Blum RA, D'Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991;114:755-7.
41. Wood N, Tan K, Purkins L, et al. Effect of omeprazole on the steady- state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003;56(Suppl 1):56-61.
42. Gubbins PO, Krishna G, Sansone-Parsons A, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 2006;50:1993-9.
43. Black DJ, Kunze KL, Wienkers LC, et al. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996;24:422-8.
44. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36:630-7.
45. Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. BrJ Clin Pharmacol 2003;56(Suppl 1):37-44.
46. Geist MJ, Egerer G, Burhenne J, Riedel KD, Mikus G. Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications. Antimicrob Agents Che-mother 2007;51:3455-6.
47. van der Lee MJ, Dawood L, ter Hofstede HJ, et al. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther 2006;80:159-68.
48. Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004;75:587-8.
49. Geist MJ, Egerer G, Burhenne J, Mikus G. Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype. Antimicrob Agents Chemother 2006;50:3227-8.
50. Balian JD, Sukhova N, Harris JW, et al. The hydroxylation of ome- prazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995;57:662-9.
51. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000;38:111-80.
52. Li L, Meier PJ, Ballatori N. Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione. Mol Pharmacol 2000;58:335-40.
53. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Phar- macokinet 2003;42:1141-60.
54. Gupta A, Unadkat JD, Mao Q. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). J Pharm Sci 2007;96:3226-35.
55. Brülggemann RJ, Donnelly JP, Aarnoutse RE, et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit 2008;30:403-11.
56. UptoDate. Lexi-Interact Online. Available at: http://www.uptodate.com/ crlsql/interact/frameset.jsp. Accessed 16 December 2008.
57. Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, Srichai W. Reduced oral itraconazole bioavailability by antacid suspension. J Clin Pharm Ther 2005;30:201-6.
58. Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992;14:165-74.
59. May DB, Drew RH, Yedinak KC, Bartlett JA. Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. Pharmacotherapy 1994;14:509-13.
60. Naef R, Schmid C, Hofer M, Minder S, Speich R, Boehler A. Itra-conazole comedication increases systemic levels of inhaled fluticasone in lung transplant recipients. Respiration 2007;74:418-22.
61. Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M. Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers. Ther Drug Monit 1999;21:304-9.
62. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996;60:54-61.
63. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998;46:49-53.
64. Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the phar- macokinetics of itraconazole. Eur J Clin Pharmacol 1998;54:159-61.
65. Ducharme MP, Slaughter RL, Warbasse LH, et al. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin Pharmacol Ther 1995;58:617-24.
66. Krishna G, Sansone-Parsons A, Kantesaria B. Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men. Curr Med Res Opin 2007;23:1415-22.
67. Krishna G, Parsons A, Kantesaria B, Mant T. Evaluation of the phar- macokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr Med Res Opin 2007;23:545-52.
68. Jaruratanasirikul S, Sriwiriyajan S. Effect of rifampicin on the phar- macokinetics of itraconazole in normal volunteers and AIDS patients. Eur J Clin Pharmacol 1998;54:155-8.
69. Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006;12:552-9.
70. Rengelshausen J, Banfield M, Riedel KD, et al. Opposite effects of short-term and long-term St John's wort intake on voriconazole phar- macokinetics. Clin Pharmacol Ther 2005;78:25-33.
71. Honig PK, Wortham DC, Hull R, Zamani K, Smith JE, Cantilena LR. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 1993;33: 1201-6.
72. Neuvonen PJ, Varhe A, Olkkola KT. The effect of ingestion time interval on the interaction between itraconazole and triazolam. Clin Pharmacol Ther 1996;60:326-31.
73. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56(6 Pt 1):601-7.
74. Ariffin H, Omar KZ, Ang EL, Shekhar K. Severe vincristine neuro- toxicity with concomitant use of itraconazole. J Paediatr Child Health 2003;39:638-9.
75. Bermudez M, Fuster JL, Llinares E, Galera A, Gonzalez C. Itracon- azole-related increased vincristine neurotoxicity: case report and review of literature. J Pediatr Hematol Oncol 2005;27:389-92.
76. Bohme A, Ganser A, Hoelzer D. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 1995;71:311-2.
77. Gillies J, Hung KA, Fitzsimons E, Soutar R. Severe vincristine toxicity in combination with itraconazole. Clin Lab Haematol 1998;20:123-4.
78. Jeng MR, Feusner J. Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2001;18:137-42.
79. Kamaluddin M, McNally P, Breatnach F, et al. Potentiation of vin-cristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr 2001;90:1204-7.
80. Murphy JA, Ross LM, Gibson BE. Vincristine toxicity in five children with acute lymphoblastic leukaemia. Lancet 1995;346:443.
81. Sathiapalan RK, Al-Nasser A, El-Solh H, Al-Mohsen I, Al-Jumaah S. Vincristine-itraconazole interaction: cause for increasing concern. J Pediatr Hematol Oncol 2002;24:591.
82. Sathiapalan RK, El-Solh H. Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature. Pediatr He- matol Oncol 2001;18:543-6.
83. Palkama VJ, Isohanni MH, Neuvonen PJ, Olkkola KT. The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. Anesth Analg 1998;87: 190-4.
84. Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. Clin Pharmacol Ther 2006;80:502-8.
85. Newberry DL, Bass SN, Mbanefo CO. A fluconazole/amitriptyline drug interaction in three male adults. Clin Infect Dis 1997;24:270-1.
86. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998;64: 58-65.
87. Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT. Plasma concentrations of inhaled budesonide and its effects on plasma cor- tisol are increased by the cytochrome P4503A4 inhibitor itraconazole. Clin Pharmacol Ther 2002;72:362-9.
88. Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S. Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itra- conazole and budesonide. Eur Respir J 2002;20:127-33.
89. Christensen J, Dupont E, Ostergaard K. Cabergoline plasma concentration is increased during concomitant treatment with itraconazole. Mov Disord 2002;17:1360-2.
90. Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther 2003;73:192-8.
91. Canafax DM, Graves NM, Hilligoss DM, Carleton BC, Gardner MJ, Matas AJ. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 1991; 51:1014-8.
92. Sud K, Singh B, Krishna VS, et al. Unpredictable cyclosporin- fluconazole interaction in renal transplant recipients. Nephrol Dial Transplant 1999;14:1698-703.
93. Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996;61:1268-72.
94. Florea NR, Capitano B, Nightingale CH, Hull D, Leitz GJ, Nicolau DP. Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. Transplant Proc 2003;35: 2873-7.
95. Leather H, Boyette RM, Tian L, Wingard JR. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2006;12:325-34.
96. Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007;27:825-34.
97. Romero AJ, Le PP, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002;71:226-34.
98. Karyekar CS, Eddington ND, Briglia A, Gubbins PO, Dowling TC. Renal interaction between itraconazole and cimetidine. J Clin Pharmacol 2004;44:919-27.
99. Hynninen VV, Olkkola KT, Leino K, et al. Effect of voriconazole on the pharmacokinetics of diclofenac. Fundam Clin Pharmacol 2007;21:651-6.
100. Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 1997;19:609-13.
101. Liu P, Foster G, Labadie RR, Gutierrez MJ, Sharma A. Pharmacoki- netic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J Clin Pharmacol 2008;48:73-84.
102. Damle B, Labadie R, Crownover P, Glue P. Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. Br J Clin Pharmacol 2008;65:523-30.
103. Andrews E, Damle BD, Fang A, et al. Pharmacokinetics and tolera- bility of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. Br J Clin Pharmacol 2008;65: 531-9.
104. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 1997;61:410-5.
105. Kantola T, Backman JT, Niemi M, Kivisto KT, Neuvonen PJ. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000;56:225-9.
106. Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivisto KT. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 2001; 69:194-200.
107. Liu P, Foster G, Labadie R, Somoza E, Sharma A. Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy. Antimicrob Agents Chemother 2007;51: 110-8.
108. Ahonen J, Olkkola KT, Neuvonen PJ. Effect ofroute ofadministration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol 1997;51:415-9.
109. Ahonen J, Olkkola KT, Takala A, Neuvonen PJ. Interaction between fluconazole and midazolam in intensive care patients. Acta Anaes- thesiol Scand 1999;43:509-14.
110. Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996;82:511-6.
111. Vanakoski J, Mattila MJ, Vainio P, Idanpaan-Heikkila JJ, Tornwall M. 150 mg fluconazole does not substantially increase the effects of 10 mg midazolam or the plasma midazolam concentrations in healthy subjects. Int J Clin Pharmacol Ther 1995;33:518-23.
112. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of itraconazole and ter- binafine on the pharmacokinetics and pharmacodynamics of mida- zolam in healthy volunteers. Br J Clin Pharmacol 1995;40:270-2.
113. Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 1998;54:53-8.
114. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itra- conazole. Clin Pharmacol Ther 1994;55:481-5.
115. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004;21:645-53.
116. Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole on the pharmacokinetics and pharmacodynam- ics of intravenous and oral midazolam. Clin Pharmacol Ther 2006;79:362-70.
117. Garazzino S, Tettoni M, Calcagno A, D'Avolio A, Bonora S, Di Perri G. Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases. J Antimicrob Chemother 2006;58:483-5.
118. Jaruratanasirikul S, Sriwiriyajan S. Pharmacokinetic study of the interaction between itraconazole and nevirapine. Eur J Clin Pharmacol 2007;63:451-6.
119. Kang BC, Yang CQ, Cho HK, Suh OK, Shin WG. Influence of flu- conazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharm Drug Dispos 2002;23:77-81.
120. Blum RA, Wilton JH, Hilligoss DM, et al. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 1991; 49:420-5.
121. Liu P, Foster G, Gandelman K, et al. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother 2007;51:3617-26.
122. Mikus G, Schowel V, Drzewinska M, et al. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cy- tochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006;80:126-35.
123. Cardiello PG, Samor T, Burger D, et al. Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients. Antivir Ther 2003;8:245-9.
124. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itracon-azole. Clin Pharmacol Ther 1998;63:332-41.
125. Manez R, Martin M, Raman D, et al. Fluconazole therapyintransplant recipients receiving FK506. Transplantation 1994;57:1521-3.
126. Shitrit D, Ollech JE, Ollech A, et al. Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction. J Heart Lung Transplant 2005;24:2148-52.
127. Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole on the pharmacokinetics and pharmacody- namics of zolpidem in healthy subjects. Br J Clin Pharmacol 2007;63:116-20.
128. Yasui N, Kondo T, Otani K, et al. Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology (Berl) 1998;139:269-73.
129. Furukori H, Kondo T, Yasui N, et al. Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced brom- peridol inschizophrenicpatients. Psychopharmacology(Berl) 1999;145: 189-92.
130. Purkins L, Wood N, Kleinermans D, Nichols D. Histamine H2-re- ceptor antagonists have no clinically significant effect on the steady- state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003;56(Suppl 1):51-5.
131. Auclair B, Berning SE, Huitt GA, Peloquin CA. Potential interaction between itraconazole and clarithromycin. Pharmacotherapy 1999;19: 1439-44.
132. Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004;103:1557-9.
133. Varis T, Kivisto KT, Backman JT, Neuvonen PJ. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin Pharmacol Ther 2000;68:487-94.
134. Saari TI, Laine K, Bertilsson L, Neuvonen PJ, Olkkola KT. Voricon- azole and fluconazole increase the exposure to oral diazepam. Eur J Clin Pharmacol 2007;63:941-9.
135. Ahonen J, Olkkola KT, Neuvonen PJ. The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of di- azepam. Fundam Clin Pharmacol 1996;10:314-8.
136. Araki K, Yasui-Furukori N, Fukasawa T, et al. Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. Eur J Clin Pharmacol 2004;60:427-30.
137. Saari TI, Laine K, Neuvonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. Eur J Clin Pharmacol 2008;64:25-30.
138. Palkama VJ, Neuvonen PJ, Olkkola KT. The CYP 3A4 inhibitor itra-conazole has no effect on the pharmacokinetics of i.v. fentanyl. Br J Anaesth 1998;81:598-600.
139. Park JY, Shon JH, Kim KA, et al. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. J Clin Psycho-pharmacol 2006;26:135-42.
140. Hynninen VV, Olkkola KT, Leino K, et al. Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen. Antimicrob Agents Chemother 2006;50:1967-72.
141. Niemi M, Tornio A, Pasanen MK, Fredrikson H, Neuvonen PJ, Back- man JT. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. Eur J Clin Pharmacol 2006;62:463-72.
142. Kazierad DJ, Martin DE, Blum RA, et al. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 1997;62:417-25.
143. Kaukonen KM, Olkkola KT, Neuvonen PJ. Fluconazole but not itra- conazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 1998;53:445-9.
144. Varis T, Kivisto KT, Backman JT, Neuvonen PJ. Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. Pharmacol Toxicol 1999;85:29- 32.
145. Masui T, Kusumi I, Takahashi Y, Koyama T. Effects of itraconazole and tandospirone on the pharmacokinetics of perospirone. Ther Drug Monit 2006;28:73-5.
146. Damkier P, Hansen LL, Brosen K. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacoki- netics of quinidine. Br J Clin Pharmacol 1999;48:829-38.
147. Kaukonen KM, Olkkola KT, Neuvonen PJ. Itraconazole increases plasma concentrations of quinidine. Clin Pharmacol Ther 1997;62: 510-7.
148. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gem- fibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 2003;46:347-51.
149. Trapnell CB, Narang PK, Li R, Lavelle JP. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann Intern Med 1996;124:573-6.
150. Jordan MK, Polis MA, Kelly G, Narang PK, Masur H, Piscitelli SC. Effects of fluconazole and clarithromycin on rifabutin and 25-O- desacetylrifabutin pharmacokinetics. Antimicrob Agents Chemother 2000;44:2170-2.
151. Jaruratanasirikul S, Kleepkaew A. Lack of effect of fluconazole on the pharmacokinetics of rifampicin in AIDS patients. J Antimicrob Che- mother 1996;38:877-80.
152. Panomvana Na Ayudhya D, Thanompuangseree N, Tansuphaswadikul S. Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS. Clin Pharmacokinet 2004;43:725-32.
153. Nicolau DP, Crowe HM, Nightingale CH, Quintiliani R. Rifampin- fluconazole interaction in critically ill patients. Ann Pharmacother 1995;29:994-6.
154. Jung SM, Kim KA, Cho HK, et al. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hy- droxyrisperidone in schizophrenic patients. Clin Pharmacol Ther 2005;78:520-8.
155. Jokinen MJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of clarith- romycin and itraconazole on the pharmacokinetics of ropivacaine. Pharmacol Toxicol 2001;88:187-91.
156. Varhe A, Olkkola KT, Neuvonen PJ. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol 1996;41:319-23.
157. Varhe A, Olkkola KT, Neuvonen PJ. Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br J Clin Pharmacol 1996;42:465-70.
158. Hynninen VV, Olkkola KT, Bertilsson L, Kurkinen K, Neuvonen PJ, Laine K. Effect of terbinafine and voriconazole on the pharmacoki- netics of the antidepressant venlafaxine. Clin Pharmacol Ther 2008;83:342-8.
159. Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol 2003;56(Suppl 1):24-9.
160. Kubo M, Koue T, Inaba A, et al. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE. Drug Metab Pharmacokinet 2005;20: 55-64.
161. Lilja JJ, Backman JT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atenolol. Basic Clin Pharmacol Toxicol 2005;97: 395-8.
162. Purkins L, Wood N, Ghahramani P, Kleinermans D, Layton G, Nichols D. No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers. Br J Clin Pharmacol 2003;56(Suppl 1):30-6.
163. Palkama VJ, Neuvonen PJ, Olkkola KT. Effect of itraconazole on the pharmacokinetics of bupivacaine enantiomers in healthy volunteers. Br J Anaesth 1999;83:659-61.
164. Buggia I, Zecca M, Alessandrino EP, et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res 1996;16:2083-8.
165. Winter HR, Trapnell CB, SlatteryJT, et al. The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283). Clin Pharmacol Ther 2004;76:313-22.
166. Damle B, Hess H, Kaul S, Knupp C. Absence of clinically relevant drug interactions following simultaneous administration of didano- sine-encapsulated, enteric-coated bead formulation with either itra- conazole or fluconazole. Biopharm Drug Dispos 2002;23:59-66.
167. Sinofsky FE, Pasquale SA. The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives. Am J Obstet Gynecol 1998;178:300.
168. Hilbert J, Messig M, Kuye O, Friedman H. Evaluation of interaction between fluconazole and an oral contraceptive in healthy women. Obstet Gynecol 2001;98:218-23.
169. Kovarik JM, Hsu CH, McMahon L, Berthier S, RordorfC. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther 2001; 70:247-54.
170. Shimizu M, Uno T, Sugawara K, Tateishi T. Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofen- adine, a substrate of P-glycoprotein. Br J Clin Pharmacol 2006;62: 372-6.
171. Shon JH, Yoon YR, Hong WS, et al. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther 2005;78: 191-201.
172. Uno T, Shimizu M, Sugawara K, Tateishi T. Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fex-ofenadine. Drug Metab Dispos 2006;34:1875-9.
173. Swaisland HC, Ranson M, Smith RP, et al. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 2005;44:1067-81.
174. Gubbins PO, McConnell SA, Gurley BJ, et al. Influence of grapefruit juice on the systemic availability of itraconazole oral solution in healthy adult
175. Ouellet D, Bramson C, Roman D, et al. Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene. Br J Clin Pharmacol 2007;63:59-66.
176. Isohanni MH, Neuvonen PJ, Palkama VJ, Olkkola KT. Effect of eryth- romycin and itraconazole on the pharmacokinetics of intravenous lignocaine. Eur J Clin Pharmacol 1998;54:561-5.
177. Isohanni MH, Neuvonen PJ, Olkkola KT. Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine. Pharmacol Toxicol 1999;84:143-6.
178. Scott G, Yih L, Yeh CM, Milosavljev S, Laurent A, Rordorf C. Lu-miracoxib: pharmacokinetic and pharmacodynamic profile when coadministered with fluconazole in healthy subjects. J Clin Pharmacol 2004;44:193-9.
179. Johnson MD, Hamilton CD, Drew RH, Sanders LL, Pennick GJ, Perfect JR. A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J Antimicrob Chemother 2003;51:453-7.
180. Lukkari E, Juhakoski A, Aranko K, Neuvonen PJ. Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite. Eur J Clin Pharmacol 1997;52: 403-6.
181. Varis T, Kivisto KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur J Clin Pharmacol 2000;56:57-60.
182. Cato A III, Cao G, Hsu A, Cavanaugh J, Leonard J, Granneman R. Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir. Drug Metab Dispos 1997;25:1104-6.
183. Koks CH, Crommentuyn KM, Hoetelmans RM, et al. The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1- infected individuals. Br J Clin Pharmacol 2001; 51:631-5.
184. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Can-tarini MV. The effect of fluconazole on the pharmacokinetics of ro-suvastatin. Eur J Clin Pharmacol 2002;58:527-31.
185. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Can-tarini MV. Effect of itraconazole on the pharmacokinetics of rosu-vastatin. Clin Pharmacol Ther 2003;73:322-9.
186. Ahonen J, Olkkola KT, Neuvonen PJ. Lack of effect of antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of tem- azepam. Ther Drug Monit 1996;18:124-7.
187. Honig PK, Worham DC, Zamani K, Mullin JC, Conner DP, Cantilena LR. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin Pharmacol Ther 1993;53:630-6.
188. Brockmeyer NH, Tillmann I, Mertins L, Barthel B, Goos M. Phar- macokinetic interaction of fluconazole and zidovudine in HIV-positive patients. Eur J Med Res 1997;2:377-83.
189. Luurila H, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. Eur J Clin Pharmacol 1998;54:163-6.
190. Jalava KM, Olkkola KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. Eur J Clin Pharmacol 1996;51:331-4.
191. Ohtani Y, Kotegawa T, Tsutsumi K, Morimoto T, Hirose Y, Nakano S. Effect of fluconazole on the pharmacokinetics and pharmacody- namics of oral and rectal bromazepam: an application of electroen- cephalography as the pharmacodynamic method. J Clin Pharmacol 2002;42:183-91.
192. Raaska K, Neuvonen PJ. Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole. Eur J Clin Pharmacol 1998;54:167-70.
193. Borin MT, Cox SR, Herman BD, Carel BJ, Anderson RD, FreimuthWW. Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients. An- timicrob Agents Chemother 1997;41:1892-7.
194. Bruzzese VL, Gillum JG, Israel DS, Johnson GL, Kaplowitz LG, Polk RE. Effect of fluconazole on pharmacokinetics of2',3'-dideoxyinosine in persons seropositive for human immunodeficiency virus. Anti- microb Agents Chemother 1995;39:1050-3.
195. Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole does not affect the steady-state pharmacokinetics of digoxin. Br J Clin Pharmacol 2003;56(Suppl 1):45-50.
196. Otsuji Y, Okuyama N, Aoshima T, et al. No effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of es-tazolam. Ther Drug Monit 2002;24:375-8.
197. De Wit S, Debier M, De Smet M, et al. Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1998;42:223-7.
198. Purkins L, Wood N, Kleinermans D, Love ER. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers. Br J Clin Pharmacol 2003;56(Suppl 1):62-8.
199. Isohanni MH, Neuvonen PJ, Olkkola KT. Effect of itraconazole on the pharmacokinetics of inhaled lidocaine. Basic Clin Pharmacol Tox- icol 2004;95:120-3.
200. Ueno K, Yamaguchi R, Tanaka K, et al. Lack of a kinetic interaction between fluconazole and mexiletine. Eur J Clin Pharmacol 1996;50:129-31.
201. Zimmermann T, Yeates RA, Riedel KD, Lach P, Laufen H. The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of omeprazole. Int J Clin Pharmacol Ther 1994;32:491-6.
202. Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gem- fibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther 2005;77:404-14.
203. Buchkowsky SS, Partovi N, Ensom MH. Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit 2005;27:322-33.
204. Dominguez-Gil HA, Sanchez NA, Garcia Sanchez MJ. Therapeutic drug monitoring of itraconazole and the relevance of pharmacokinetic interactions. Clin Microbiol Infect 2006;12(Suppl 7):97-106.
205. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006;50:1570-2.
206. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005;35:509-13.